The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.
Borderline personality disorder is a significantly disabling disturbance often arising in adolescents or young adults. In the absence of demonstrated effective treatments in this population, this open prospective study evaluated the effect of low dose (3 mg per day) flupenthixol in 13 rigorously diagnosed adolescents with borderline personality disorder. Therapeutic outcome over eight weeks of treatment assessed across measures of impulsivity, depression/dysphoria, general psychopathology and global functioning showed significant improvement in all spheres. These findings suggest that low dose flupenthixol may have a role to play in the short-term treatment of this population.
Kutcher
S
S
Department of Psychiatry, University of Toronto, North York, Ontario, Canada.
Papatheodorou
G
G
Reiter
S
S
Gardner
D
D
D000293:Adolescent; D000328:Adult; D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis; D005260:Female; D005475:Flupenthixol / Q000008:administration & dosage* / Q000009:adverse effects; D016352:Group Homes; D006801:Humans; D008297:Male; D009460:Neurologic Examination / Q000187:drug effects; D010552:Personality Assessment; D011446:Prospective Studies; D016896:Treatment Outcome
D005475:Flupenthixol